



(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 33/20* (2006.01)*A61K 9/08* (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:

PCT/EP2022/069154

(22) International Filing Date:

08 July 2022 (08.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2110146.4 14 July 2021 (14.07.2021) GB

(71) Applicant: **HYPO-STREAM LIMITED** [GB/GB]; 9 Beech House, Melbourn Science Park, Melbourn Cambridgeshire SG8 6HB (GB).(72) Inventors: **DAKIN, Myles**; c/o Hypo-Stream Limited, 9 Beech House, Melbourn Science Park, Melbourn Cambridgeshire SG8 6HB (GB). **ASPINALL, Richard**; c/o Hypo-Stream Limited, 9 Beech House, Melbourn Science Park, Melbourn Cambridgeshire SG8 6HB (GB). **KENNY, Thomas**; c/o Hypo-Stream Limited, 9 Beech House, Mel-


bourn Science Park, Melbourn Cambridgeshire SG8 6HB (GB).

(74) Agent: **MARKS & CLERK LLP**; 62-68 Hills Road, Cambridge, Cambridgeshire CB2 1LA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TREATMENT OF RESPIRATORY CONDITIONS

**FIG. 1**

(57) Abstract: The present invention relates to a hypochlorite solution for use in the prevention or treatment of a respiratory condition or disease in a patient; preferably a mammal, more preferably a human. The present invention also relates to a hypochlorite solution for use in the prevention or treatment of an inflammatory or auto-immune response, condition or disease in a patient, preferably a mammal, more preferably a human, wherein administration of the hypochlorite solution is by inhalation of the hypochlorite solution. The hypochlorite solution comprises hypochlorite in a concentration range of about 0.005-0.2 wt% (about 50-2000 ppm by wt).

[Continued on next page]



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*